文献速递血栓与止血

Microlyse:靶向VWF清除微血管血栓的溶栓剂

Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis.
PubMed 文献 · Blood · 2022-01-01

本文描述了一种融合蛋白Microlyse的开发与表征,该蛋白由靶向VWF的CT/CK结构域的高亲和力VHH与uPA蛋白酶结构域组成,用于在微血栓上局部激活纤溶酶原。在活化内皮细胞和凝集研究中,Microlyse可靶向破坏血小板-VWF复合物;在等摩尔浓度下,其降解微血栓的速度比caplacizumab*阻断血小板-VWF相互作用快七倍。在ADAMTS13-/-小鼠TTP模型中,Microlyse比caplacizumab*更有效地减轻血小板减少和组织损伤,且不影响尾夹出血模型中的止血。

要点

  • Microlyse是由靶向VWF的VHH和uPA蛋白酶结构域组成的融合蛋白。
  • 在等摩尔浓度下,Microlyse降解微血栓的速度比caplacizumab*快七倍。
  • 在ADAMTS13-/-小鼠TTP模型中,Microlyse比caplacizumab*更有效地减轻血小板减少和组织损伤。

核心结论

  • 靶向VWF的Microlyse溶栓是治疗TTP的有效策略,可能对其他VWF驱动的血栓性疾病有价值。

研究设计与样本

  • 开发与表征融合蛋白Microlyse,并在体外实验和ADAMTS13-/-小鼠TTP模型中进行评价。

主要发现

  • 在等摩尔浓度下,Microlyse降解微血栓的速度比caplacizumab*阻断血小板-VWF相互作用快七倍。
  • 在ADAMTS13-/-小鼠TTP模型中,Microlyse比caplacizumab*更有效地减轻血小板减少和组织损伤(表现为血浆乳酸脱氢酶活性以及PAI-1和纤维蛋白原水平升高)。
  • 在尾夹出血模型中,Microlyse不影响止血。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombotic microangiopathies are hallmarked by attacks of disseminated microvascular thrombosis. In thrombotic thrombocytopenic purpura (TTP), this is caused by a rise in thrombogenic ultra-large von Willebrand factor (VWF) multimers because of ADAMTS13 deficiency. We previously reported that systemic plasminogen activation is therapeutic in a TTP mouse model. In contrast to its natural activators (ie, tissue plasminogen activator and urokinase plasminogen activator [uPA]), plasminogen can directly bind to VWF. For optimal efficacy and safety, we aimed to focus and accelerate plasminogen activation at sites of microvascular occlusion. We here describe the development and characterization of Microlyse, a fusion protein consisting of a high-affinity VHH targeting the CT/CK domain of VWF and the protease domain of uPA, for localized plasminogen activation on microthrombi. Microlyse triggers targeted destruction of platelet-VWF complexes by plasmin on activated endothelial cells and in agglutination studies. At equal molar concentrations, Microlyse degrades microthrombi sevenfold more rapidly than blockade of platelet-VWF interactions with a bivalent humanized VHH (caplacizumab*). Finally, Microlyse attenuates thrombocytopenia and tissue damage (reflected by increased plasma lactate dehydrogenase activity, as well as PAI-1 and fibrinogen levels) more efficiently than caplacizumab* in an ADAMTS13-/- mouse model of TTP, without affecting hemostasis in a tail-clip bleeding model. These findings show that targeted thrombolysis of VWF by Microlyse is an effective strategy for the treatment of TTP and might hold value for other forms of VWF-driven thrombotic disease.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. de Maat S, Clark CC, Barendrecht AD, et al. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis. Blood. 2022. PMID: 34752601. doi:10.1182/blood.2021011776

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。